Alivus Life Sciences Ltd

Alivus Life Sciences Q3 Results: Steady Growth in Revenue & Profit 📈

- Revenue from operations in Q3 rose to ₹6,728.89M (vs. ₹6,418.44M YoY).

- Total income for Q3 reached ₹6,868.17M (up from ₹6,523.00M YoY).

- Profit before tax improved to ₹1,983.92M (vs. ₹1,851.47M YoY).

- Net profit (after tax) grew to ₹1,502.61M (vs. ₹1,369.60M YoY).

- Basic EPS increased to ₹12.25 (from ₹11.18 YoY).

- Nine-month total income stood at ₹19,003.48M, with net profit of ₹4,018.22M.

- Exceptional item of ₹256.57M due to new labour codes.

- Single reporting segment: Active Pharmaceutical Ingredient (API).

- 600,631 employee stock options outstanding as of Dec 31, 2025.